McAdam LLC’s Teva Pharmaceuticals TEVA Stock Holding History

McAdam LLC’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-373	Closed	-$8K	–	543
2018 Q3	$8K	Buy	+373	New	+$8.66K	﹤0.01%	368

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

McAdam LLC's TEVA Position: Q4 2018 in Review

McAdam LLC sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 373 shares — an estimated $8K sold.

McAdam LLC first reported a position in TEVA in Q3 2018 and held it in 1 quarter. The position peaked at $8K in Q3 2018. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

McAdam LLC reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 373 Teva Pharmaceuticals shares in Q4 2018, an estimated $8K.
McAdam LLC first reported a position in Teva Pharmaceuticals in Q3 2018 and held it in 1 quarter.
McAdam LLC's Teva Pharmaceuticals position peaked at $8K in Q3 2018.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.